Navigation Links
Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
Date:6/11/2013

Philadelphia, PA, June 11, 2013 There is growing evidence that a gene variant that reduces the plasticity of the nervous system also modulates responses to treatments for mood and anxiety disorders. In this case, patients with posttraumatic stress disorder, or PTSD, with a less functional variant of the gene coding for brain-derived neurotrophic factor (BDNF), responded less well to exposure therapy.

This gene has been implicated previously in treatment response. Basic science studies have convincingly shown that BDNF levels are an important modifier of the therapeutic effects of antidepressants in animal models. Other researchers have made similar findings in a small group of depressed patients treated with the rapid-acting antidepressant ketamine. Low BDNF plasma levels also have been linked to poorer effects of cognitive rehabilitation in schizophrenia. BDNF infused directly into the infralimbic prefrontal cortex in rats was found to extinguish conditioned fear, and BDNF levels were found to modulate the amount of fear extinction.

"Findings are accumulating to suggest that BDNF is an important modifier of the responses to a number of clinical interventions, presumably because BDNF is such an important regulator of neuroplasticity, i.e., the ability of the brain to adapt," said Dr. John Krystal, Editor of Biological Psychiatry.

In this study, researchers from Australia and Puerto Rico teamed up to investigate the influence of the BDNF Val66Met genotype on response to exposure therapy in patients with PTSD. They recruited 55 patients, all of whom participated in an 8-week exposure-based cognitive behavior therapy program.

Exposure therapy is currently the most effective treatment for PTSD, although it does not work for everyone. This type of therapy is delivered over multiple one-on-one sessions with a trained therapist, with a goal of reducing patients' fear and anxiety.

They found that patients with the Met-66 allele of BDNF, compared with patients with the Val/Val allele, showed poorer response to exposure therapy.

"This paper reflects an important and significant advance, in translating recent ground-breaking findings in animal and human neuroscience into clinically anxious populations," said first author Dr. Kim Felmingham.

She added, "Findings from this study support a widely held, but largely untested, hypothesis that extinction is necessary for exposure therapy. It also provides evidence that genotypes influence response to cognitive behavior therapy."

This finding supports prior evidence and highlights the importance of considering genotypes as potential predictor variables in clinical trials of exposure therapy.


'/>"/>

Contact: Rhiannon Bugno
Biol.Psych@utsouthwestern.edu
214-648-0880
Elsevier
Source:Eurekalert

Related biology news :

1. Stress hormones: Good or bad for posttraumatic stress disorder risk?
2. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
3. Some corals like it hot: Heat stress may help coral reefs survive climate change
4. Lizard moms may prepare their babies for a stressful world
5. Researcher awarded $1 million for stress-associated disease and aging research
6. Low-income moms under stress may overfeed infants
7. Study offers new insights into the effects of stress on pregnancy
8. NUS-led research team discovers how bacteria sense salt stress
9. LSUHSC research finds treating stress prevented new MS brain lesions
10. Red hair is a sign of oxidative stress in wild boars, but gray is a-ok
11. Bend or stretch? How stressful is hyperflexion of horses necks?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... READING, England , May ... ( http://www.indegene.com ), ein führender Anbieter von ... Life-Science-Branche, Pharmaunternehmen und Gesundheitsorganisationen, und TranScrip ( ... innovativen wissenschaftlichen Support-Services für den gesamten Produktlebenszyklus, ... heute den Ausbau ihrer bestehenden Allianz an. ...
(Date:5/26/2016)... NEW YORK , May 26, 2016 ... announced today that it will be a featured presenter at ... 2016 in New York City at ... Denis Corin , Q BioMed Inc. CEO, is scheduled ... presentation will cover the company,s business strategy, recent developments and ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... decades. FireflySci cuvettes are used in leading laboratories all over the globe. ... day. , In addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the ... in surgery and surgery of the hand by the National Board of Physicians ... going above and beyond in his pursuit of providing the most comprehensive, effective ...
Breaking Biology Technology: